NASDAQ
18.60USD
+1.19 (+6.80%)
We have scored 3 news catalysts on Braveheart Bio, Inc. (BRVE) over the past 12 months. The biggest single-day move next to one of them came Aug 10, 2026, when BRVE closed −8.2%: “Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?”. Coverage across the window leans positive (average ticker sentiment +0.83). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.3B
P/E
—
EPS
—
Beta
0.00
52W range
16.7-32
Day range
16.89–18.99
Open
17.55
Prev close
17.41
Volume
702.1K
Avg volume
494.6K
Dividend
0.00
IPO
2026-08-06
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Braveheart Bio, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for BRVE: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
